Moxifloxacin hydrochloride

SKU: orb1310715

Description

Moxifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic with enhanced activity against Gram-positive and atypical pathogens. It is widely used in research for in vitro susceptibility testing and in vivo infection model studies. Its use has been associated with transient ALT elevations and rare cases of clinically apparent liver injury.

Research Area

Infectious Disease & Virology, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 186826-86-8
• MW: 437.89
• Purity: 99.91% (May vary between batches)
• Formula: C₂₁H₂₅ClFN₃O₄
• SMILES: O(C)C1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@]4([C@@](C3)(NCCC4)[H])[H])C5CC5.Cl
• Target: Topoisomerase|||Antibacterial|||Antibiotic
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.54 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:88 mg/mL (200.96 mM);H2O:15 mg/mL (34.26 mM)

Bioactivity

• In Vivo:
  Moxifloxacin exhibits a broad spectrum of antibacterial activity both in vitro and clinically against various pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, H. parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. It functions by stabilizing the DNA-drug-enzyme complex, thereby inhibiting ATP-dependent topoisomerase II (DNA gyrase) and topoisomerase IV, critical enzymes for bacterial DNA replication, transcription, repair, and recombination.
  Read more...
• In Vitro:
  In a mouse model simulating human disease, treatment with Moxifloxacin combined with RIF (Rifampicin)/PZA (Pyrazinamide) shortened the therapy duration by two months compared to the standard regimen of INH (Isoniazid)/RIF/PZA. Similarly, biweekly administration of Rifampicin/Moxifloxacin/PZA led to stable cure after four months, whereas daily treatment with Rifampicin/INH/PZA resulted in cure after six months.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

community-acquired, chronic, bronchitis, Bacterial, BAY 128039, BAY 12-8039, BAY128039, BAY-128039, BAY12-8039 HCl, antimicrobial, Antibiotic, acute, 8-methoxyquinolone, Inhibitor, exacerbations, Moxifloxacin, Moxifloxacin HCl, Moxifloxacin Hydrochloride, Moxifloxacin hydrochloride, inhibit, Topo IV, Topo II, pneumonia, sinusitis

Compound Identifiers

PubChem CID

101526